Business Context and Reporting Period
Company: Rocket Pharmaceuticals, Inc. (RCKT)
Filing Type: Form 8-K (Current Report)
Date of Report: September 15, 2026
Reporting Period: Single event date (September 15, 2026)
Context: The filing discloses a significant clinical development milestone regarding the Company's lead asset, RP-A501, for the treatment of Danon disease.
Key Financial Metrics
This Form 8-K is a disclosure of a material event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Updates
The primary material change reported is the alignment with the U.S. Food and Drug Administration (FDA) regarding the global pivotal Phase 2 trial of RP-A501. Key elements confirmed include:
- Continued Enrollment and Dosing: The FDA agreed to the continuation of patient enrollment and dosing.
- Recalibrated Dose: A specific recalibrated dose for the trial has been established.
- Pivotal Population: The trial will focus on a 12-patient pivotal population.
- Endpoints: Established 12-month co-primary endpoints for the study.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the FDA alignment. No specific financial guidance or forward-looking revenue projections are included in this text.
Risks and Contingencies: The filing notes that the information provided under Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings, except as expressly set forth. This limits the legal liability of the forward-looking statements contained in the press release.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed clinical trial protocols and specific endpoint definitions.
- Confirm the timeline for the 12-month co-primary endpoints and expected data readout dates.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial data.
- Monitor subsequent filings for any updates on the 12-patient enrollment progress.